Zacks Investment Research disclosed Conatus Pharmaceuticals Inc (NASDAQ:CNAT), upping its stock price target to $2.25 earlier today
- Updated: October 4, 2016
Zacks Investment Research upped the price target of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) to $2.25 reporting a possible upside of 0.08%.
Previously on Tuesday September 22, 2015, H.C. Wainwright reported about Conatus Pharmaceuticals Inc (NASDAQ:CNAT) raised the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 2.46%.
Yesterday Conatus Pharmaceuticals Inc (NASDAQ:CNAT) traded 6.12% higher at $2.09. The company’s 50-day moving average is $1.91 and its 200-day moving average is $2.23. The last stock close price is down -6.78% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,492,665 shares of the stock were exchanged, up from an average trading volume of 444,397
See Chart Below
Conatus Pharmaceuticals Inc has a 52 week low of $1.40 and a 52 week high of $4.62 The company’s market cap is currently $0.
General Information About Conatus Pharmaceuticals Inc (NASDAQ:CNAT)
Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.